A California man’s lawsuit alleging Abilify caused his compulsive gambling may be the “tip of the iceberg,” one the plaintiff’s attorneys told Bloomberg BNA (Thomas v. Bristol-Myers Squibb Co., C.D. Cal., 16-00326, complaint 1/19/16).
Defendants Bristol-Myers Squibb Co., Otsuka Pharmaceutical Co. and subsidiary Otsuka America Pharmaceutical Inc. knew or should have known Abilify causes and exacerbates a risk of uncontrollable behaviors, yet failed to warn patients or the medical community in the U.S. that the drug is linked with compulsive gambling, plaintiff Daniel F. Thomas alleges.
Thomas says he lost more than $75,000 after starting Abilify in ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.